Results 111 to 120 of about 27,357 (215)

Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 1, Page 29-45, January 2026.
There is a concerning trend of widespread and severe superficial fungal infections caused by a new pathogen—Trichophyton indotineae—resistant to standard antifungal therapies. T. indotineae is now spreading globally and evolving. There is increasing urgency for healthcare providers and policy makers to initiate surveillance systems and antifungal ...
Aditya K. Gupta, Susmita, Hien C. Nguyen, Amanda Liddy, Mesbah Talukder, Tong Wang, Lee Magal, Anuradha Chowdhary, Avner Shemer, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +11 more
wiley   +1 more source

In Vitro Antifungal Susceptibility of Clinically Relevant Species Belonging to Aspergillus Section Flavi [PDF]

, 2013
The in vitro antifungal susceptibility of 77 isolates belonging to different clinically relevant species of Aspergillus section Flavi, including those of different phylogenetic clades of A.
Cano, Josep, Colombo, Arnaldo L., Goncalves, Sarah S., Guarro, Josep, Stchigel, Alberto M.   +4 more
core   +2 more sources

Characterisation of Antifungal Prophylaxis and Therapy Among Inpatients With Haematological Malignancies in Non‐Research Clinical Setting: A Multicentre Italian Experience

Mycoses, Volume 69, Issue 1, January 2026.
ABSTRACT Background Invasive fungal infections (IFI) are a prominent cause of morbidity and mortality among patients with haematological malignancies (HMs). Diagnostic work‐up excluding IFI is mandatory in case of persistent fever while antifungal treatment (AFT) is started.
Criscuolo Marianna, Bonanni Matteo, Martino Giordana, Farina Francesca, Verga Luisa, Marchesi Francesco, Basilico Claudia, Del Principe Maria Ilaria, Tisi Maria Chiara, Cattaneo Chiara, Picardi Marco, Bonuomo Valentina, Fracchiolla Nicola, Candoni Anna, Perruccio Katia, Stanzani Marta, Cesaro Simone, Fanci Rosa, Dargenio Michela, Forghieri Fabio, Ballanti Stelvio, Cudillo Laura, Cuccaro Annarosa, Carraro Francesca, Zama Daniele, Armiento Daniele, Garzia Maria Grazia, Spolzino Angelica, Busca Alessandro, Pagano Livio   +29 more
wiley   +1 more source

Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae [PDF]

, 2017
Azole-resistant strains of Aspergillus fumigatus have been detected and the underlying molecular mechanisms of resistance characterized. Point mutations in the cyp51A gene have been proved to be related to azole resistance in A.
Alcazar-Fuoli, L., Cuenca-Estrella, M., Mellado, E., Sanglard, D.   +3 more
core  

Pharmacokinetic Interaction Between Isavuconazole and Rifabutin in a Real‐World Setting

Mycoses, Volume 69, Issue 1, January 2026.
ABSTRACT Background Since rifabutin has less severe drug interactions, it is preferred over rifampin when administered concomitantly with azole antifungals. However, limited data exist to evaluate this interaction. Methods This was a single‐centre study of hospitalised patients who received concomitant isavuconazole and rifabutin prior to plasma ...
Sunish Shah, Lloyd Clarke, Tiffany Lee, Leah Georgiades, Brandon J. Smith, Raman Venkataramanan, Ryan M. Rivosecchi   +6 more
wiley   +1 more source

Cladophialophora bantiana: a rare cause of fungal brain abscess. Clinical aspects and new therapeutic options [PDF]

, 2017
Black molds or dematiaceous fungi are rare etiologic agents of intracerebral abscesses and such infections carry a high mortality of up to 70% despite combined surgical and antifungal therapy.
Bijlenga, Philippe, Garbino, Jorge, Garzoni, Christian, Markham, Lydia   +3 more
core  

High‐dose posaconazole for azole‐resistant aspergillosis and other difficult‐to‐treat mould infections

Mycoses (Berlin), 2019
Oral follow‐up therapy is problematic in moulds with reduced azole‐susceptibility, such as azole‐resistant Aspergillus fumigatus infection. Currently, only intravenous liposomal amphotericin B (L‐AmB) is advocated by guidelines for the treatment of azole‐
A. Schauwvlieghe, Jochem B. Buil, P. Verweij, R. Hoek, J. Cornelissen, N. Blijlevens, S. Henriet, B. Rijnders, R. Brüggemann   +8 more
semanticscholar   +1 more source

In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of apergillus terreus Sensu Stricto [PDF]

, 2015
The antifungal susceptibilities of 40 clinical and environmental isolates of A. terreus sensu stricto to amphotericin B, terbinafine, itraconazole, and voriconazole were determined in accordance with CLSI document M38-A2.
Cattana, Maria Emilia, Fernández, Mariana Soledad, Giusiano, Gustavo Emilio, Iovannitti, Cristina A., Lass Flörl, Cornelia, Rojas, Florencia Dinorah, Sosa, Maria de Los Angeles   +6 more
core   +1 more source

Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.

PLoS Neglected Tropical Diseases, 2018
Chagas' disease is responsible for significant mortality and morbidity in Latin America. Current treatments display variable efficacy and have adverse side effects, hence more effective, better tolerated drugs are needed.
Lorna M MacLean, John Thomas, Michael D Lewis, Ignacio Cotillo, David W Gray, Manu De Rycker   +5 more
doaj   +1 more source

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients

Critical Care, 2019
Background The population pharmacokinetics of total and unbound posaconazole following intravenous administration has not yet been described for the critically ill patient population. The aim of this work was, therefore, to describe the total and unbound
Fekade B. Sime, Catherine J. Byrne, Suzanne Parker, Janine Stuart, Jenie Butler, Therese Starr, Saurabh Pandey, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts   +9 more
doaj   +1 more source